CoChat
Sign Up
Cited by 21Hepatocellular Carcinoma Treatment and PrognosisSkin and Cellular Biology ResearchCell Adhesion Molecules Research

Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment

Open access
Cheng, Chiung-Chi, Chao, Wei-Ting, Liao, Chen-Chun, Tseng, Yu-Hui, Lai, Yen-Chang Clark, Lai, Yih-Shyong, Hsu, Yung-Hsiang, Liu, Yi-Hsiang·2018·Cell Adhesion & Migration
DOI 10.1080/19336918.2017.1288789PMC PMC5810502
Open this paper in CoChat — free accountOpen PDF

Abstract

Plectin involved in activation of kinases in cell signaling pathway and plays important role in cell morphology and migration. Plectin knockdown promotes cell migration by activating focal adhesion kinase and Rac1-GTPase activity in liver cells. Sorafenib is a multi-targeting tyrosine kinase inhibitor that improves patient survival on hepatocellular carcinoma. The aim of this study is to investigate the correlation between the expression of plectin and cell migration as well as the sensitivity of hepatoma cell lines exposing to sorafenib. Hepatoma cell lines PLC/PRF/5 and HepG2 were used to examine the level of plectin expression and cell migration in comparison with Chang liver cell line. In addition, sensitivity of the 3 cell lines to sorafenib treatment was also measured. Expression of plectin was lower in PLC/PRF/5 and HepG2 hepatoma cells than that of Chang liver cells whereas HepG2 and PLC/PRF/5 cells exhibit higher rate of cell migration in trans-well migration assay. Immunohistofluorecent staining on E-cadherin revealed the highest rate of collective cell migration in HepG2 cells and the lowest was found in Chang liver cells. Likewise, HepG2 cell line was most sensitive to sorafenib treatment and Chang liver cells exhibited the least sensitivity. The drug sensitivity to sorafenib treatment showed inverse correlation with the expression of plectin. We suggest that plectin deficiency and increased E-cadherin in hepatoma cells were associated with higher rates of cell motility, collective cell migration as well as higher drug sensitivity to sorafenib treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19336918.2017.1288789

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 32 · Cited by 21

Research works printed but not linked: 30

  1. [1]Huber F, Boire A, Lopez MP, Koenderink GH Cytoskeletal crosstalk: when three different personalities team up. Curr Opin Cell Biol 2015; 32: 39- 47; PMID:25460780; https://doi.org/ 10.1016/j.ceb.2014.10.005 25460780 · DOI
  2. [2]Wiche G Role of plectin in cytoskeleton organization and dynamics. J Cell Sci 1998; 111(Pt 17): 2477- 86; PMID:9701547 9701547
  3. [3]Castanon MJ, Walko G, Winter L, Wiche G Plectin-intermediate filament partnership in skin, skeletal muscle, and peripheral nerve. Histochem Cell Biol 2013; 140(1): 33- 53; PMID:23748243; https://doi.org/ 10.1007/s00418-013-1102-0 23748243 PMC3695321 · DOI
  4. [4]Osmanagic-Myers S, Gregor M, Walko G, Burgstaller G, Reipert S, Wiche G Plectin-controlled keratin cytoarchitecture affects MAP kinases involved in cellular stress response and migration. J Cell Biol 2006; 174(4): 557- 68; PMID:16908671; https://doi.org/ 10.1083/jcb.200605172 16908671 PMC2064261 · DOI
  5. [5]Winter L, Wiche G The many faces of plectin and plectinopathies: pathology and mechanisms. Acta Neuropathol 2013; 125(1): 77- 93; PMID:22864774; https://doi.org/ 10.1007/s00401-012-1026-0 22864774 · DOI
  6. [6]Omary MB, Ku NO, Toivola DM Keratins: guardians of the liver. Hepatology 2002; 35(2): 251- 7; PMID:11826396; https://doi.org/ 10.1053/jhep.2002.31165 11826396 · DOI
  7. [7]Cheng CC, Liu YH, Ho CC, Chao WT, Pei RJ, Hsu YH, Yeh KT, Ho LC, Tsai MC, Lai YS The influence of plectin deficiency on stability of cytokeratin18 in hepatocellular carcinoma. J Mol Histol 2008; 39(2): 209- 16; PMID:18038249; https://doi.org/ 10.1007/s10735-007-9155-9 18038249 · DOI
  8. [8]Liu YH, Ho CC, Cheng CC, Chao WT, Pei RJ, Hsu YH, Lai YS Cytokeratin 18-mediated disorganization of intermediate filaments is induced by degradation of plectin in human liver cells. Biochem Biophys Res Commun 2011; 407(3): 575- 80; PMID:21420381; https://doi.org/ 10.1016/j.bbrc.2011.03.066 21420381 · DOI
  9. [9]Liu YH, Cheng CC, Ho CC, Chao WT, Pei RJ, Hsu YH, Ho LC, Shiu BH, Lai YS Plectin deficiency on cytoskeletal disorganization and transformation of human liver cells in vitro. Med Mol Morphol 2011; 44(1): 21- 6; PMID:21424933; https://doi.org/ 10.1007/s00795-010-0499-y 21424933 · DOI
  10. [10]Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012; 142(4): 957- 66.e12; PMID:22202459; https://doi.org/ 10.1053/j.gastro.2011.12.039 22202459 PMC3321110 · DOI
  11. [11]Krakhmal NV, Zavyalova MV, Denisov EV, Vtorushin SV, Perelmuter VM Cancer Invasion: Patterns and Mechanisms. Acta Naturae 2015; 7(2): 17- 28; PMID:26085941 26085941 PMC4463409
  12. [12]Clark AG, Vignjevic DM Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 2015; 36: 13- 22; PMID:26183445; https://doi.org/ 10.1016/j.ceb.2015.06.004 26183445 · DOI
  13. [13]Friedl P, Hegerfeldt Y, Tusch M Collective cell migration in morphogenesis and cancer. Int J Dev Biol 2004; 48(5–6): 441- 9; PMID:15349818; https://doi.org/ 10.1387/ijdb.041821pf 15349818 · DOI
  14. [14]Legate KR, Wickstrom SA, Fassler R Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009; 23(4): 397- 418; PMID:19240129; https://doi.org/ 10.1101/gad.1758709 19240129 · DOI
  15. [15]Cheng CC, Lai YC, Lai YS, Hsu YH, Chao WT, Sia KC, Tseng YH, Liu YH Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase. Cancer Cell Int 2015; 15: 29- 35; PMID:25861244; https://doi.org/ 10.1186/s12935-015-0177-1 25774093 PMC4358909 · DOI
  16. [16]Forner A, Llovet JM, Bruix J Hepatocellular carcinoma. Lancet 2012; 379(9822): 1245- 55; PMID:22353262; https://doi.org/ 10.1016/S0140-6736(11)61347-0 22353262 PMC13537732 · DOI
  17. [17]Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099- 109; PMID:15466206; https://doi.org/ 10.1158/0008-5472.CAN-04-1443 15466206 · DOI
  18. [18]Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98(5): 326- 34; PMID:16507829; https://doi.org/ 10.1093/jnci/djj069 16507829 · DOI
  19. [19]Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378- 90; PMID:18650514; https://doi.org/ 10.1056/NEJMoa0708857 18650514 · DOI · Paper page
  20. [20]Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25- 34; PMID:19095497; https://doi.org/ 10.1016/S1470-2045(08)70285-7 19095497 · DOI · Paper page
  21. [21]Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57(4): 821- 9; PMID:22727733; https://doi.org/ 10.1016/j.jhep.2012.06.014 22727733 PMC12261288 · DOI
  22. [22]Li L, Hartley R, Reiss B, Sun Y, Pu J, Wu D, Lin F, Hoang T, Yamada S, Jiang J, et al. E-cadherin plays an essential role in collective directional migration of large epithelial sheets. Cell Mol Life Sci 2012; 69(16): 2779- 89; PMID:22410739; https://doi.org/ 10.1007/s00018-012-0951-3 22410739 PMC3459324 · DOI
  23. [23]Cai D, Chen SC, Prasad M, He L, Wang X, Choesmel-Cadamuro V, Sawyer JK, Danuser G, Montell DJ Mechanical Feedback through E-Cadherin Promotes Direction Sensing during Collective Cell Migration. Cell 2014; 157(5): 1146- 59; PMID:24855950; https://doi.org/ 10.1016/j.cell.2014.03.045 24855950 PMC4118667 · DOI
  24. [24]van Zijl F, Krupitza G, Mikulits W Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 2011; 728(1–2): 23- 34; PMID:21605699; https://doi.org/ 10.1016/j.mrrev.2011.05.002 21605699 PMC4028085 · DOI
  25. [25]Vasioukhin V, Fuchs E Actin dynamics and cell-cell adhesion in epithelia. Curr Opin Cell Biol 2001; 13(1): 76- 84; PMID:11163137; https://doi.org/ 10.1016/S0955-0674(00)00177-0 11163137 · DOI
  26. [26]Mattila PK, Lappalainen P Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 2008; 9(6): 446- 54; PMID:18464790; https://doi.org/ 10.1038/nrm2406 18464790 · DOI
  27. [27]Chung YC, Wei WC, Hung CN, Kuo JF, Hsu CP, Chang KJ, Chao WT Rab11 collaborates E-cadherin to promote collective cell migration and indicates a poor prognosis in colorectal carcinoma. Eur J Clin Invest 2016; 46(12): 1002- 11; PMID:27696383; https://doi.org/ 10.1111/eci.12683 27696383 · DOI
  28. [28]Galmiche A, Chauffert B, Barbare JC New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 2014; 346(2): 159- 62; PMID:24380851; https://doi.org/ 10.1016/j.canlet.2013.12.028 24380851 · DOI
  29. [29]Godin C, Louandre C, Bodeau S, Diouf M, Saidak Z, Conte MA, Chauffert B, Barbare JC, Barget N, Trinchet JC, et al. Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. Anticancer Res 2015; 35(3): 1803- 8; PMID:25750346 25750346
  30. [30]Li GM, Wang YG, Pan Q, Wang J, Fan JG, Sun C RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. Int J Clin Exp Pathol 2014; 7(3): 1085- 92; PMID:24696725 24696725 PMC3971312

Authors
Cheng, C.-C., Chao, W.-T., Liao, C.-C., Tseng, Y.-H., Lai, Y.-C. C., Lai, Y.-S., Hsu, Y.-H., & Liu, Y.-H.
Affiliations
  • Providence University (TW)
  • Tunghai University (TW)
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
  • Tzu Chi University (TW)
Corresponding author
Liu, Yi-Hsiang
ORCID
Venue
Cell Adhesion & Migration
Publisher
Informa UK Limited
Published
2017-02-17
Volume
12
Issue
1
Pages
19-27
ISSN
  • 1933-6918 (ISSN-L)
  • 1933-6926
DOI
10.1080/19336918.2017.1288789
PMC
PMC5810502
OpenAlex
W2588308784
Cited by
21
References
32
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2021: 7 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2
FWCI
1.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Adhesion & Migration (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Chang Bing Show Chwan Memorial Hospital (RD104005, RD105050, RD105051)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Skin and Cellular Biology Research
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
Keywords
plectin, hepatocellular carcinoma, hepatoma cells, cell migration, sorafenib sensitivity, tyrosine kinase inhibitors, E-cadherin, focal adhesion kinase, Rac1, collective cell migration, PLC/PRF/5, HepG2 cells, Chang liver cells
MeSH terms
Sorafenib, Antineoplastic Agents, Cell Movement, Cell Survival, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Signal Transduction, Apoptosis, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Plectin, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review